Trials / Recruiting
RecruitingNCT06263959
A Randomized, Double-blind, Placebo-controlled Phase IIa Clinical Study to Evaluate the Safety and Efficacy of GST-HG131 Tablets in Patients With Chronic Hepatitis B
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 45 (estimated)
- Sponsor
- Fujian Akeylink Biotechnology Co., Ltd. · Industry
- Sex
- All
- Age
- 35 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
A randomized, double-blind, placebo-controlled Phase IIa clinical study to evaluate the safety and efficacy of GST-HG131 tablets in patients with chronic hepatitis B
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GST-HG131 | GST-HG131 will be administered. |
| DRUG | Placebo to match GST-HG131 | Placebo to match GST-HG131 will be administered. |
Timeline
- Start date
- 2023-12-26
- Primary completion
- 2025-04-01
- Completion
- 2025-05-01
- First posted
- 2024-02-16
- Last updated
- 2025-03-05
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06263959. Inclusion in this directory is not an endorsement.